Company:  ACCELERON PHARMA INC (XLRN)
Form Type:  424B5
Filing Date:  6/30/2020 
CIK:  0001280600 
Address:  128 SIDNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  617-649-9200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$105.30  
Change: 
6.13 (6.18%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$6.18B
Trade XLRN now with 

© 2020  
Description of Business
We are a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. We have focused and prioritized our research and development activities within three key therapeutic areas: hematology, pulmonary and neuromuscular. Hematology In November 2019, the U.S.
Register and access this filing in:     
  FORM 424B5
    Summary
    Dilution
    Underwriting
    Experts
    RISK FACTORS
    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    RATIO OF COMBINED FIXED CHARGES AND PREFERRED STOCK ...
    PLAN OF DISTRIBUTION
    DESCRIPTION OF CAPITAL STOCK
    Transfer Agent and Registrar
    DESCRIPTION OF WARRANTS
    WHERE YOU CAN FIND MORE INFORMATION
      INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
    LEGAL MATTERS